These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36264560)

  • 1. Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma.
    Kim C; Yang H; Kim I; Kang B; Kim H; Kim H; Lee WS; Jung S; Lim HY; Cheon J; Chon HJ
    JAMA Oncol; 2022 Dec; 8(12):1825-1829. PubMed ID: 36264560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
    Yang H; Kang B; Ha Y; Lee SH; Kim I; Kim H; Lee WS; Kim G; Jung S; Rha SY; Gaillard VE; Cheon J; Kim C; Chon HJ
    JHEP Rep; 2023 Apr; 5(4):100672. PubMed ID: 36866388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants.
    Nakabori T; Kunimasa K; Kawabata M; Higashi S; Mukai K; Kawamura T; Inoue T; Tamiya M; Nishino K; Ohkawa K
    Cancer Med; 2024 Jun; 13(12):e7430. PubMed ID: 38924675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
    Salem R; Li D; Sommer N; Hernandez S; Verret W; Ding B; Lencioni R
    Cancer Med; 2021 Aug; 10(16):5437-5447. PubMed ID: 34189869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma.
    Su CW; Teng W; Shen EY; Huang BS; Lin PT; Hou MM; Wu TH; Tsan DL; Hsieh CH; Wang CT; Chai PM; Lin CY; Lin SM; Lin CC
    Oncologist; 2024 Jul; 29(7):e922-e931. PubMed ID: 38530254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
    Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
    BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC.
    Yang J; Choi J; Choi WM; Kim KM; Lee HC; Shim JH
    Liver Int; 2024 Apr; 44(4):907-919. PubMed ID: 38291863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma.
    Miura R; Ono A; Yano S; Amioka K; Naruto K; Yamaoka K; Fujii Y; Uchikawa S; Fujino H; Nakahara T; Murakami E; Kawaoka T; Miki D; Tsuge M; Hayes CN; Oka S
    Medicine (Baltimore); 2024 Aug; 103(34):e39289. PubMed ID: 39288227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Nishikawa H; Tsuji K; Ishikawa T; Tajiri K; Koshiyama Y; Toyoda H; Ogawa C; Hatanaka T; Kakizaki S; Kawata K; Ohama H; Tada F; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Nishimura T; Imai M; Kosaka H; Naganuma A; Matono T; Aoki T; Kuroda H; Yata Y; Koizumi Y; Nakamura S; Enomoto H; Kaibori M; Hiasa Y; Kudo M; ;
    Aliment Pharmacol Ther; 2024 Jul; 60(2):233-245. PubMed ID: 38716823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment.
    Chen CT; Feng YH; Yen CJ; Chen SC; Lin YT; Lu LC; Hsu CH; Cheng AL; Shao YY
    Hepatol Int; 2022 Oct; 16(5):1199-1207. PubMed ID: 35986846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
    Eso Y; Takeda H; Taura K; Takai A; Takahashi K; Seno H
    Curr Oncol; 2021 Oct; 28(5):4157-4166. PubMed ID: 34677270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum interleukin-6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis.
    Suzuki T; Matsuura K; Suzuki Y; Okumura F; Nagura Y; Sobue S; Matoya S; Miyaki T; Kimura Y; Kusakabe A; Narahara S; Tokunaga T; Nagaoka K; Murakami S; Inoue T; Kuroyanagi K; Kawamura H; Fujiwara K; Nojiri S; Kataoka H; Tanaka Y
    J Gastroenterol Hepatol; 2024 Oct; 39(10):2158-2168. PubMed ID: 38943340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Aoki T; Kuroda H; Yata Y; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M;
    Liver Int; 2024 Jan; 44(1):113-124. PubMed ID: 37789669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma.
    Kawamura Y; Kobayashi M; Shindoh J; Matsumura M; Okubo S; Muraishi N; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
    Oncology; 2022; 100(6):320-330. PubMed ID: 35231914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y;
    J Gastroenterol Hepatol; 2023 Aug; 38(8):1389-1397. PubMed ID: 37231943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of hepatocellular carcinoma with "pseudoprogression" followed by complete response to atezolizumab plus bevacizumab.
    Odagiri N; Tamori A; Kotani K; Motoyama H; Kawamura E; Hagihara A; Fujii H; Uchida-Kobayashi S; Enomoto M; Kawada N
    Clin J Gastroenterol; 2023 Jun; 16(3):392-396. PubMed ID: 36739366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of Survival in Patients With Hepatocellular Cancer Receiving Atezolizumab and Bevacizumab.
    Ledenko M; Mercado L; Patel T
    Am J Clin Oncol; 2024 Mar; 47(3):105-109. PubMed ID: 38047447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.
    Ben Khaled N; Möller M; Jochheim LS; Leyh C; Ehmer U; Böttcher K; Pinter M; Balcar L; Scheiner B; Weich A; Leicht HB; Zarka V; Ye L; Schneider J; Piseddu I; Öcal O; Rau M; Sinner F; Venerito M; Gairing SJ; Förster F; Mayerle J; De Toni EN; Geier A; Reiter FP
    JHEP Rep; 2024 Jun; 6(6):101065. PubMed ID: 38798717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.